Bellevue Group Ag Biomarin Pharmaceutical Inc Transaction History

Bellevue Group Ag

$4.31 Billion
Q1 2025

A detailed history of Bellevue Group Ag transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bellevue Group Ag holds 368,373 shares of BMRN stock, worth $20.2 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

368,373

Previous 329,021 11.96%

Holding current value

$20.2 Million

Previous $21.6 Million 20.41%

% of portfolio

0.6%

Previous 0.43%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$61.25 - $72.83 $2.41 Million - $2.87 Million	39,352 Added 11.96%	368,373 $26 Million
Q4 2024 Feb 14, 2025	SELL	$61.93 - $70.49 $121,073 - $137,807	-1,955 Reduced 0.59%	329,021 $21.6 Million
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $19.2 Million - $26.2 Million	278,744 Added 533.67%	330,976 $23.3 Million
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $20.1 Million - $24.9 Million	-269,555 Reduced 83.77%	52,232 $4.3 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $334,318 - $394,911	-3,989 Reduced 1.22%	321,787 $28.1 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $1.84 Million - $2.38 Million	-24,112 Reduced 6.89%	325,776 $31.4 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $911,610 - $1.01 Million	-10,716 Reduced 2.97%	349,888 $31 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $27.1 Million - $31.3 Million	312,159 Added 644.36%	360,604 $31.3 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $1.07 Million - $1.44 Million	-12,240 Reduced 20.17%	48,445 $4.71 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $582,048 - $781,266	7,192 Added 13.44%	60,685 $6.28 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $1.66 Million - $1.96 Million	-20,260 Reduced 27.47%	53,493 $4.54 Million
Q2 2022 Aug 11, 2022	SELL	$71.48 - $86.85 $60,543 - $73,561	-847 Reduced 1.14%	73,753 $6.11 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $237,696 - $296,608	3,200 Added 4.48%	74,600 $5.75 Million
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $1.41 Million - $1.8 Million	19,700 Added 38.1%	71,400 $6.31 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $837,424 - $957,264	11,200 Added 27.65%	51,700 $4 Million
Q2 2021 Aug 12, 2021	BUY	$75.51 - $84.79 $264,285 - $296,765	3,500 Added 9.46%	40,500 $3.38 Million
Q1 2021 May 12, 2021	BUY	$74.73 - $90.69 $2.77 Million - $3.36 Million	37,000 New	37,000 $2.79 Million
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $5.53 Million - $10.1 Million	-76,900 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $381,840 - $596,256	4,800 Added 6.66%	76,900 $9.49 Million
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $349,713 - $474,565	4,900 Added 7.29%	72,100 $6.09 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $4.32 Million - $5.8 Million	67,200 New	67,200 $5.68 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $3.87 Million - $4.53 Million	-45,969 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $152,266 - $201,533	-1,900 Reduced 3.97%	45,969 $3.91 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $154,968 - $174,438	-1,650 Reduced 3.33%	47,869 $4.64 Million
Q2 2018 Aug 07, 2018	BUY	$76.01 - $99.03 $392,895 - $511,886	5,169 Added 11.66%	49,519 $4.67 Million
Q1 2018 May 09, 2018	SELL	$77.67 - $92.63 $54,369 - $64,841	-700 Reduced 1.55%	44,350 $3.6 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $302,850 - $356,737	-3,750 Reduced 7.68%	45,050 $4.02 Million
Q3 2017 Nov 13, 2017	SELL	$80.6 - $94.95 $1.31 Million - $1.54 Million	-16,200 Reduced 24.92%	48,800 $4.54 Million
Q2 2017 Aug 14, 2017	BUY	N/A	65,000	65,000 $5.9 Million

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Biomarin Pharmaceutical Inc Transaction History